Feed aggregator

AstraZeneca to acquire Icosavax

World Pharma News - Tue, 12/12/2023 - 11:00
AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform.

The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV),

AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchase

Biospace news - Tue, 12/12/2023 - 02:00
AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchase 12/12/2023

Major breakthrough for severe asthma treatment

World Pharma News - Mon, 12/11/2023 - 11:00
A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects.

The findings from the multinational SHAMAL study, published in The Lancet, demonstrated that 92% of patients using the biologic therapy benralizumab could safely reduce inhaled steroid dose and more than 60% could stop all use.

FDA approves first gene therapies to treat patients with sickle cell disease

World Pharma News - Fri, 12/08/2023 - 19:00
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy.

Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun

Biospace news - Fri, 12/08/2023 - 02:00
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun 12/8/2023

Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun

Biospace news - Fri, 12/08/2023 - 02:00
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun 12/8/2023

FDA Approves Two Gene Therapies for Sickle Cell, First CRISPR-Based Medicine

Biospace news - Fri, 12/08/2023 - 02:00
FDA Approves Two Gene Therapies for Sickle Cell, First CRISPR-Based Medicine 12/8/2023

Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study

Biospace news - Fri, 12/08/2023 - 02:00
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study 12/8/2023

Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal

Biospace news - Fri, 12/08/2023 - 02:00
Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal 12/8/2023

Rebranded Spyre Therapeutics Secures $180M to Advance IBD Antibody Pipeline

Biospace news - Fri, 12/08/2023 - 02:00
Rebranded Spyre Therapeutics Secures $180M to Advance IBD Antibody Pipeline 12/8/2023

Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case

Biospace news - Fri, 12/08/2023 - 02:00
Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case 12/8/2023

Axcella Health Becomes the Latest Flagship Company to Close its Doors

Biospace news - Fri, 12/08/2023 - 02:00
Axcella Health Becomes the Latest Flagship Company to Close its Doors 12/8/2023

Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook

Biospace news - Fri, 12/08/2023 - 02:00
Biopharma Funding, Deals Fall Sharply in 2023 in ‘Strategic’ Shift: PitchBook 12/8/2023

BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer

Biospace news - Fri, 12/08/2023 - 02:00
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer 12/8/2023